View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
August 1, 2019

UK researchers trial new device for monitoring dizziness

Researchers at the University of East Anglia (UEA) and the Norfolk and Norwich University Hospital (NNUH) in the UK have completed a clinical trial assessing a dizziness monitoring device.

Researchers at the University of East Anglia (UEA) and the Norfolk and Norwich University Hospital (NNUH) in the UK have completed a clinical trial assessing a dizziness monitoring device.

Free Report
img

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.
by GlobalData
Enter your details here to receive your free Report.

The Continuous Ambulatory Vestibular Assessment (CAVA) device is designed as a wearable headset to diagnose the most common sources of dizziness.

According to the researchers, it is lightweight, durable and can be worn day and night. The device monitors head and eye movements in order to enable analysis of dizziness attacks outside hospitals.

When tested for detecting eye flicker (nystagmus), the device was found to be 99% accurate.

The study evaluated the accuracy, reliability and safety of CAVA in 17 subjects who did not have dizziness problems.

Participants wore the device for up to 30 days, allowing the capture of 9,000 hours of eye and head movement data, equivalent to 405 days.

According to study principal investigator John Phillips, the first phase of the trial involved artificially induced nystagmus in healthy patients.

In addition to 99% detection sensitivity, the device showed a specificity of 98.6% in detecting short periods of the induced eye flicker.

The results have been published in the Scientific Reports journal, where researchers noted that the CAVA device was reliable and operated an ambulatory monitor with a favourable tolerability profile.

Phillips said: “Following years of development, I’m delighted that this project was successful in identifying short periods of visually induced nystagmus with a high degree of accuracy.

“The success of this trial has proven the potential of this to fulfil a clinical need and establishing a new field of medicine: vestibular telemetry.”

Based on these findings, the researchers plan to perform another study to investigate the device’s diagnostic accuracy in patients with dizziness problems.

Related Companies

Free Report
img

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network